

AmeriChoice Pharmacy & Therapeutics Committee Minutes

March 11, 2010


Meeting Date: March 11, 2010

Location: Via conference call

Members in Attendance:

Members Absent:

Guests:



Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
Meeting called to order		5:06 PM		
I. Minutes of previous meetings	R. Brekosky	Minutes of December AMC P&T meeting were reviewed	Minutes reviewed, approved	17:0
II. New Formulations	J. Bellicini	1) Valturma (valsartan/alsikiren) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	2) Twynsta (telmisartan/amlodipine) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	3) Acuvail (ketorolac 0.45% ophthalmic solution) Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	4) Onsolis (fentanyl buccal film) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	5) Zipsor (diclofenac potassium liquid-filled capsules) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	6) Edluar (zolpidem sublingual) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	7) Metozolv ODT (metoclopramide orally disintegrating) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	8) Oforta (fludarabine oral tablet) Recommendation: Categorize as Essential Drug, add as preferred with PA on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	9) Intuniv (guanfacine extended release) Recommendation: Categorize as Optional Inclusion, add as preferred with ST on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	D. Morgan	10) Extavia (interferon beta-1b) Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
III. New Drug Reviews	A. Hindman	1) Bepreve (bepotastine)	Motion made, seconded, and carried to accept recommendation	17:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
III. New Drug Reviews CONT'D	A. Hindman	Recommendation: Categorize as Essential Class, remain non-preferred on the Medicaid PDLs		
	A. Hindman	2) Embeda (morphine sulfate/naltrexone) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	A. Hindman	3) Onglyza (saxagliptin) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	A. Hindman	4) Fanapt (iloperidone) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	A. Hindman	5) Votrient (pazopanib) Recommendation: Categorize as Essential Drug, add as preferred with PA on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	16:0
	A. Hindman	6) Stelara (ustekinumab) Recommendation: Categorize as Optional Inclusion, remain non-preferred on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	D. Morgan	7) Sabril (vigabatrin) Recommendation: Categorize as Essential Drug, add as preferred with PA on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	D. Morgan	8) Ilaris/Arcalyst (canakinumab/rilonacept) Recommendation: Categorize as Essential Drug, add as preferred with PA on the Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
IV. Class Reviews	D. Moore	1) Prenatal Vitamins Recommendation: Confirm class review, Approve proposed list of preferred prenatal vitamins	Motion made, seconded, and carried to accept recommendation	17:0
V. PDL Additions/Modifications	J. Bellicini	1) Smoking Cessation Products Recommendation: Remove quantity limit on nicotine products, monthly quantity limits will remain Recommendation: Remove prior authorization requirement on Chantix, quantity limit will remain	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	2) Urea Products Recommendation: Add Urea 40% cream and lotion as preferred to Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	3) Ed A-Hist Recommendation: Add Ed A-Hist as preferred to Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	16:0
VI. Old Business	J. Bellicini	1) Invega Sustenna Recommendation: Add Invega Sustenna as preferred on the Medicaid PDLs with a quantity limit	Motion made, seconded, and carried to accept recommendation	17:0
	J. Bellicini	2) Gleevec Recommendation: Addition of prior authorization to the AmeriChoice legacy Medicaid PDLs	Motion made, seconded, and carried to accept recommendation	17:0
VII. Clinical Guidelines - Pharmacy	A. Hindman	1) Provigil/Nuvigil	Motion made, seconded, and carried to accept recommendation	17:0
	A. Hindman	2) Sensipar	Motion made, seconded, and carried to accept recommendation	16:0
	A. Hindman	3) Effient	Motion made, seconded, and carried to accept recommendation	17:0
	A. Hindman	4) Multaq	Motion made, seconded, and carried to accept recommendation	17:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
	D. Morgan	5) Ilaris/Arcalyst	Motion made, seconded, and carried to accept recommendation	17:0

Agenda Item	Speaker	Discussion	Conclusions/Recommendations	Voting Totals
VII. Clinical Guidelines - Pharmacy CONT'D	D. Morgan	6) Colony Stimulating Factors	Motion made, seconded, and carried to accept recommendation	17:0
VIII. Clinical Guidelines - Medical	D. Morgan	1) Osteoporosis Agents	Motion made, seconded, and carried to accept recommendation	17:0
IX. Quality Monitoring	R. Brekosky	1) The Quality Management Reports for the 4th quarter of 2009 were reviewed	Motion made, seconded, and carried to accept recommendation	16:0
	L. Cormier	2) The Concurrent and Retrospective DUR Reports for the 4th quarter of 2009 were reviewed		
	J. Bellicini	3) The grievance and appeals statistics for the 4th quarter of 2009 were reviewed		
	S. Balog	4) The pharmacist and medical director IRR results for the 1st quarter of 2010 were reviewed		
Adjournment		6:55 PM		

Votes not totaling 17 are the result of abstentions.

NOTE: Actions documented in these minutes document what transpired at the meeting and do not serve as notice of formulary/PDL change. All formulary/PDL changes must be approved by the Department of Public Welfare. Formulary/PDL changes are only official once approved and subsequently posted/distributed in a change notice.